Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 104.9% from a year ago
Other current liabilities stood at $21.7M at the end of Q1 FY2026, up 104.9% from a year earlier and up 28.3% from the prior quarter.
Context
- Other current liabilities amounted to 33.7% of total assets at the end of Q1 FY2026, down 4.2 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +104.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 16.92M USD
- Year-over-year change
- -10.7%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.92M | -10.7% |
| FY2024 | 2024-12-31 | 18.94M | +44.2% |
| FY2023 | 2023-12-31 | 13.13M | — |
| FY2022 | 2022-12-31 | 0 | +100.0% |
| FY2021 | 2021-12-31 | (29K) | — |
Other Current Liabilities vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +104.9% is the 3rd highest of 10, against a peer median of +1.9%.
- Other current liabilities amounts to 33.7% of total assets for UNCY, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $21.7M USD | +104.9% | — | 33.7% | |
| Mar 2026 | $5.53M USD | +323.0% | +39.7% | 2.9% | |
| Mar 2026 | $4.3M USD | +392.8% | — | 4.1% | |
| Mar 2026 | $4.12M USD | -31.7% | +41.2% | 2.3% | |
| Mar 2026 | $2.42M USD | -13.0% | +16.1% | 2.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $2.17M USD | +1.9% | +27.8% | 2.0% |
CBUSCibus, Inc. | Mar 2026 | $2.12M USD | -31.3% | +132.8% | 0.7% |
| Mar 2026 | $1.11M USD | +9.0% | -19.4% | 0.5% | |
| Mar 2026 | $159K USD | -39.1% | -35.7% | 0.3% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | -CA$427K CAD | +50.8% | — | 1.8% |
| Peer median (excluding UNCY) | — | +1.9% | +27.8% | 2.0% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.